7,8-dihydroxyflavone ameliorates scopolamine-induced Alzheimer-like pathologic dysfunction.

Scopolamine (Sco) can induce amyloid β (Aβ) deposition, oxidative stress, synaptic dysfunction, and learning/memory impairment as observed in Alzheimer's disease (AD), the most common form of dementia affecting more than 25 million elderly people worldwide. Herein we explored the protective effect of 7,8-dihydroxyflavone (7,8-DHF) on Sco-induced Aβ deposition, oxidative stress, synaptic dysfunction, and learning/memory defects. Rats were randomly divided into four groups (n=12 for each group). The control group received normal saline (NS); the Sco group received Sco (1 mg/kg per day) intraperitoneally (i.p.) for 2 weeks. Mice in the Sco+7,8-DHF group received 1 mg/kg per day 7,8-DHF i.p. for 2 weeks, followed by Sco (1 mg/kg per day)+1 mg/kg per day 7,8-DHF (i.p.) for another 2 weeks. The 7,8-DHF group received 1 mg/kg per day 7,8-DHF (i.p.) for 4 weeks. Results showed that the supplement of 7,8-DHF significantly reversed Aβ deposition, oxidative stress, synaptic dysfunction, and cognitive defects. Our data suggest that 7,8-DHF might serve as a promising therapeutic candidate for attenuating Sco-induced AD-like pathological dysfuntion.

[1]  Robert W. Peoples,et al.  Nature of the neurotoxic membrane actions of amyloid-β on hippocampal neurons in Alzheimer's disease , 2014, Neurobiology of Aging.

[2]  Zhen Yan,et al.  β-Amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3 , 2014, Neurobiology of Aging.

[3]  Hui Tang,et al.  Acetyl-l-carnitine rescues scopolamine-induced memory deficits by restoring insulin-like growth factor II via decreasing p53 oxidation , 2014, Neuropharmacology.

[4]  C. Duarte,et al.  BDNF-induced local protein synthesis and synaptic plasticity , 2014, Neuropharmacology.

[5]  J. Prickaerts,et al.  7,8-Dihydroxyflavone improves memory consolidation processes in rats and mice , 2013, Behavioural Brain Research.

[6]  S. Wiese,et al.  7,8-Dihydroxyflavone leads to survival of cultured embryonic motoneurons by activating intracellular signaling pathways , 2013, Molecular and Cellular Neuroscience.

[7]  E. Castrén,et al.  The Impact of Bdnf Gene Deficiency to the Memory Impairment and Brain Pathology of APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease , 2013, PloS one.

[8]  Xiangjian Zhang,et al.  Nobiletin protects against cerebral ischemia via activating the p-Akt, p-CREB, BDNF and Bcl-2 pathway and ameliorating BBB permeability in rat , 2013, Brain Research Bulletin.

[9]  J. Kim,et al.  Alzheimer's phenotypes induced by overexpression of human presenilin 2 mutant proteins stimulate significant changes in key factors of glucose metabolism. , 2013, Molecular medicine reports.

[10]  Dong-Hyun Kim,et al.  Ginsenosides Rg5 and Rh3 protect scopolamine-induced memory deficits in mice. , 2013, Journal of ethnopharmacology.

[11]  Juan Li,et al.  Bis(9)-(−)-nor-meptazinol as a novel dual-binding AChEI potently ameliorates scopolamine-induced cognitive deficits in mice , 2013, Pharmacology Biochemistry and Behavior.

[12]  A. Cavalli,et al.  Pharmacological Characterization of Memoquin, a Multi-Target Compound for the Treatment of Alzheimer's Disease , 2013, PloS one.

[13]  Hui Tang,et al.  Melatonin Attenuates Scopolamine-Induced Memory/Synaptic Disorder by Rescuing EPACs/miR-124/Egr1 Pathway , 2012, Molecular Neurobiology.

[14]  S. W. Bihaqi,et al.  Supplementation of Convolvulus pluricaulis attenuates scopolamine-induced increased tau and Amyloid precursor protein (AβPP) expression in rat brain , 2012, Indian journal of pharmacology.

[15]  Yan Zeng,et al.  7,8‐dihydroxyflavone rescues spatial memory and synaptic plasticity in cognitively impaired aged rats , 2012, Journal of neurochemistry.

[16]  Sun Young Lee,et al.  Attenuation of scopolamine-induced cognitive dysfunction by obovatol , 2012, Archives of Pharmacal Research.

[17]  Golnaz Yadollahi Khales,et al.  Agmatine protects against scopolamine-induced water maze performance impairment and hippocampal ERK and Akt inactivation , 2012, Neuropharmacology.

[18]  R. Riek,et al.  A Novel Neurotrophic Drug for Cognitive Enhancement and Alzheimer's Disease , 2011, PloS one.

[19]  Yang Liu,et al.  A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone , 2010, Proceedings of the National Academy of Sciences.

[20]  Roberto Cappai,et al.  The redox chemistry of the Alzheimer's disease amyloid β peptide , 2007 .

[21]  E. Castrén,et al.  Role of neurotrophic factors in depression. , 2007, Current opinion in pharmacology.

[22]  J. Apter New Drug Development --- Alzheimer' Disease , 1994, Neuropsychopharmacology.

[23]  Dong Hyun Kim,et al.  Angelica keiskei ameliorates scopolamine-induced memory impairments in mice. , 2013, Biological & pharmaceutical bulletin.

[24]  M. Golechha,et al.  Studies on effects of Emblica officinalis (Amla) on oxidative stress and cholinergic function in scopolamine induced amnesia in mice. , 2012, Journal of environmental biology.

[25]  P. Fischer,et al.  Folate and Alzheimer: when time matters , 2012, Journal of Neural Transmission.

[26]  T. Nabeshima,et al.  Phosphatidylinositol 3-kinase: a molecule mediating BDNF-dependent spatial memory formation , 2003, Molecular Psychiatry.